The speediest device developer is Roche, but a look at companies’ strategies shows the perils of relying on bought-in tech.
The Danish group seizes an opportunity to focus on what it does best, but its ill-fated flirtation with oncology continues.
Neon Therapeutics is due to unveil the first rigorous test of its neoantigen approach to fighting tumours, while Neurotrope makes a brave bid in Alzheimer's.
Sanofi might only get the US go-ahead for its dengue vaccine Dengvaxia in a narrow population, leaving the door open for its rival Takeda.
Novavax awaits phase III data with its respiratory syncytial virus vaccine ResVax, while Mallinckrodt hopes to bounce back with its next big pipeline hope, CPP-1X plus…
The amyloid beta hypothesis persists in spite of repeated failure as biopharma refines targets and mechanisms of action.
Takeda will soon report phase III results with its dengue fever vaccine, while Regenxbio needs an improvement with its cholesterol-lowering gene therapy candidate,…
The tiny biotech has wasted no time in jumping on the oncolytic virus deal-making bandwagon, but dilution is nevertheless still likely.
Medicare Advantage plans have been cleared to seek cheaper alternatives for biologicals beginning next year.